{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:49:37Z","timestamp":1740142177159,"version":"3.37.3"},"reference-count":60,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2018,1,2]]},"DOI":"10.1080\/14737167.2017.1359542","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T14:53:59Z","timestamp":1500994439000},"page":"83-91","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness of dolutegravir\/abacavir\/lamivudine in HIV-1 treatment-Naive (TN) patients in France"],"prefix":"10.1080","volume":"18","author":[{"given":"Gilles","family":"Pialoux","sequence":"first","affiliation":[{"name":"Service des Maladies Infectieuses et Tropicales, AP-HP H\u00f4pital Tenon, PARIS, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Service de Virologie, Inserm UMR_S 1136, UPMC Univ Paris 06, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles FoixParis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Cawston","sequence":"additional","affiliation":[{"name":"Real World Strategy & Analytics, Mapi Group, Nanterre, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Guilmet","sequence":"additional","affiliation":[{"name":"Real World Strategy & Analytics, Mapi Group, Nanterre, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Finkielsztejn","sequence":"additional","affiliation":[{"name":"Medical affairs, ViiV Healthcare, Rueil-Malmaison, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Laurisse","sequence":"additional","affiliation":[{"name":"EU Payer Solution & Access Manager, Viiv Healthcare, Rueil-Malmaison, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Aubin","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Viiv Healthcare, Rueil-Malmaison, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,7,31]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834dce6e"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a3946"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit757"},{"key":"CIT0004","unstructured":"Morlat P Prise en charge m\u00e9dicale des personnes vivant avec le VIH \u2013 Actualisation 2014 du Rapport 2013 \u2013 Sous la direction du Pr Phillipe Morlat et sous l\u2019\u00e9gide du CNS et de l\u2019ANRS 2014 [updated 2014]. [cited 2015 May 11]. Available from: http:\/\/www.sante.gouv.fr\/IMG\/pdf\/experts-vih_actualisations2014.pdf"},{"key":"CIT0005","unstructured":"Morlat P Prise en charge m\u00e9dicale des personnes vivant avec le VIH \u2013 recommandation du groupe d\u2019experts \u2013 Sous la direction du Pr Phillipe Morlat et sous l\u2019\u00e9gide du CNS et de l\u2019ANRS \u2013 Initiation d\u2019un premier traitement antir\u00e9troviral 2017. [2017 Jun 2]. Available from: https:\/\/cns.sante.fr\/wp-content\/uploads\/2017\/01\/experts-vih_initiation.pdf"},{"key":"CIT0006","unstructured":"EPAR summary for the public \u2013 Triumeq: European Medicines Agency (EMA); [updated 8 2014]."},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0361-6"},{"volume-title":"A phase III, randomized, double-blind study of the safety and efficacy of dolutegravir plus abacavir-lamivudine fixed-dose combination therapy administered QD compared to atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects","year":"2012","author":"Pappa K","key":"CIT0008"},{"volume-title":"A phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir\/ritonavir (DRV\/r) 800 mg\/100 mg once daily each administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral naive adult subjects","year":"2013","author":"Wannamaker P","key":"CIT0009"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70257-3"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215541"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61221-0"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0071-0"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145885"},{"volume-title":"14th European AIDS Conference","year":"2013","author":"Patel DA","key":"CIT0015"},{"volume-title":"Efficacy and safety of dolutegravir relative to commonly-used 3rd-agents at 96 weeks in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis","year":"2014","author":"Patel DA","key":"CIT0016"},{"volume-title":"XIX International AIDS Conference","year":"2012","author":"Rockstroh JK","key":"CIT0017"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283316a5e"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803152"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1310\/hct1102-80"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1086\/650002"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1662"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ee3d82"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830285fb"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61049-6"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708978"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1759"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d7350"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01060.x"},{"volume-title":"XIX International AIDS Conference","year":"2012","author":"Eron JJ","key":"CIT0030"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283612419"},{"key":"CIT0032","unstructured":"Base des M\u00e9dicaments et Informations Tarifaires: assurance Maladie - ameli.f; 2015 [updated 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 19; cited 2015 Mar 30]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/bdm_it\/index.php?p_site=AMELI"},{"volume-title":"Biologie M\u00e9dicale - Nomenclature des actes: Caisse Nationale de l\u2019Assurance Maladie des Travailleurs Salari\u00e9s","year":"2014","key":"CIT0033"},{"key":"CIT0034","unstructured":"Les tarifs conventionnels: assurance Maladie en ligne - ameli.fr; 2012 [updated 2012 jun 21; cited 2012 21; cited 2014 jun 21; cited 2014 Oct 21; cited 2014 Oct 30]. Available from: http:\/\/www.ameli.fr\/professionnels-de-sante\/infirmiers\/votre-convention\/les-tarifs-conventionnels.php"},{"key":"CIT0035","unstructured":"Les tarifs conventionnels - Tarifs applicables aux pharmaciens biologistes: assurance Maladie en ligne - ameli.fr; 2011 [updated 2011 Dec 6; cited 2011 Dec 6; cited 2014 Dec 6; cited 2014 Oct 6; cited 2014 Oct 30]. Available from: http:\/\/www.ameli.fr\/professionnels-de-sante\/directeurs-de-laboratoires-d-analyses-medicales\/votre-convention\/les-tarifs-conventionnels.php"},{"key":"CIT0036","unstructured":"Remboursement d\u2019une consultation m\u00e9dicale - Consultation du m\u00e9decin correspondant (pour un suivi r\u00e9gulier - Sp\u00e9cialiste secteur 1 ou secteur 2 avec option de coordination: service-Public.fr; 2014 [updated 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 8; cited 2014 Oct 30]. Available from: http:\/\/vosdroits.service-public.fr\/particuliers\/F1069.xhtml#N101BF"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X98018002S11"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.09.1507"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.009"},{"key":"CIT0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2013.03.430","volume-title":"Cost-effectiveness of elvitegravir\/cobicistat\/emtricitabine\/tenofovir compared with efavirenz\/emtricitabine\/tenofovir as first-line HIV antiretroviral therapy in the US adult population","author":"Juday T","year":"2013"},{"volume-title":"International Society for Pharmacoeconomics and Outcomes Research, 4th Asia Pacific Conference","year":"2010","author":"Tilden D","key":"CIT0041"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.79"},{"volume-title":"Cost-effectiveness of rilpivirine- or efavirenz-based regimens for treatment-naive, HIV-1-infected patients: NHS England perspective","year":"2012","author":"Girod I","key":"CIT0043"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-2-201301150-00002"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834e87e6"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12468"},{"key":"CIT0047","unstructured":"Padilla M, Gonzalez-Cordon A, Rojas J, et al. Tolerability of integrase inhibitors in a real-life setting. International workshop on comorbidities and adverse drug reations in HIV. New York, NY: Antiviral Therapy; 2016. A28."},{"key":"CIT0048","first-page":"19","volume-title":"Abstract TUPEB256. 8th International AIDS Society Conference","author":"Lepik KJ","year":"2015"},{"volume-title":"Conference on Retroviruses and Opportunistic Infections","year":"2017","author":"Hsu R","key":"CIT0049"},{"volume-title":"Conference on Retroviruses and Opportunistic Infections","year":"2017","author":"Llibre JM","key":"CIT0050"},{"volume-title":"Poster P106. HIV","year":"2016","author":"Baldin G","key":"CIT0051"},{"volume-title":"Poster P230. HIV","year":"2016","author":"Madeddu G","key":"CIT0052"},{"volume-title":"Poster P133. HIV","year":"2016","author":"Postel N","key":"CIT0053"},{"volume-title":"Poster P108. HIV","year":"2016","author":"Tau L","key":"CIT0054"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164753"},{"volume-title":"ESCP-NSF SYMPOSIUM","year":"2016","author":"Morales A","key":"CIT0056"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1177\/2050312116675813"},{"volume-title":"Australasian HIV & AIDS Conference","year":"2016","author":"Ferrer E","key":"CIT0058"},{"volume-title":"Poster P116. HIV","year":"2016","author":"Vivancos-Gallego M","key":"CIT0059"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000519"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2017.1359542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T06:49:12Z","timestamp":1599288552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2017.1359542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,31]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,2]]}},"alternative-id":["10.1080\/14737167.2017.1359542"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2017.1359542","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"type":"print","value":"1473-7167"},{"type":"electronic","value":"1744-8379"}],"subject":[],"published":{"date-parts":[[2017,7,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}